Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
RPRX - Royalty Pharma plc
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$53.75
DETAILS
HIGH:
$63.00
LOW:
$45.00
MEDIAN:
$53.50
CONSENSUS:
$53.75
DOWNSIDE:
1.38%
Stock News
Royalty Pharma: Strong Execution, Expanding Pipeline And More Firepower Ahead
Portfolio Receipts increased 10% to $925 million, while Royalty Receipts grew 13% to $887 million. Q1 confirmed a supportive, broad-based momentum. Management's 2030 Portfolio Receipts target of $4.7 billion increasingly appears conservative. Recent funding agreements with Johnson & Johnson, alongside prior collaborations with Biogen, Merck, and Teva, strengthen Royalty Pharma's positioning. Capital flexibility and buybacks remain meaningful tailwinds. We remain buyers.
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma plc (RPRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Royalty Pharma to present at upcoming investor conferences
NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:
RPRX vs. AMGN: Which Stock Is the Better Value Option?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Royalty Pharma (RPRX) and Amgen (AMGN). But which of these two stocks presents investors with the better value opportunity right now?
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
Royalty Pharma plc (RPRX) Q1 2026 Earnings Call Transcript
Royalty Pharma PLC (RPRX) Hit a 52 Week High, Can the Run Continue?
Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Royalty Pharma (RPRX) Q1 Earnings and Revenues Surpass Estimates
Royalty Pharma (RPRX) came out with quarterly earnings of $1.3 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $1.06 per share a year ago.
Royalty Pharma reports first quarter 2026 results
Portfolio Receipts growth of 10% to $925 million; Royalty Receipts growth of 13% Net cash provided by operating activities of $718 million Raised full year 2026 guidance: Portfolio Receipts expected to be $3,325 million to $3,450 million NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts. “Royalty Pharma has delivered a strong start to 2026 across multiple dimensions.
Codexis (CDXS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Codexis (CDXS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients' lives.
Royalty Pharma Launches Global Translational Prize to Recognize Breakthrough Scientific Innovation
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the launch of the Royalty Pharma Translational Prize, which recognizes exceptional achievements in translational medicine. The Prize will honor scientific breakthroughs that bridge the gap between fundamental discovery and the development of new medicines that improve and extend patients' lives. It will include a $1 million award distributed among one or more established scientists whose work has translated unique scientific insights into medicines with significant impact, particularly contributions not yet recognized by the field's most prominent awards.
Royalty Pharma Declares Second Quarter 2026 Dividend
NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2026 of $0.235 per Class A ordinary share.
Royalty Pharma to Announce First Quarter 2026 Financial Results on May 6, 2026
NEW YORK, April 15, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2026 financial results on Wednesday, May 6, 2026 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.
Can Royalty Pharma (RPRX) Keep the Earnings Surprise Streak Alive?
Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Aberdeen Group plc Acquires 98,191 Shares of Royalty Pharma PLC $RPRX
Aberdeen Group plc grew its stake in shares of Royalty Pharma PLC (NASDAQ: RPRX) by 17.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 661,416 shares of the biopharmaceutical company's stock after purchasing an additional 98,191 shares during the quarter. Aberdeen Group
Royalty Pharma (NASDAQ:RPRX) CFO Terrance Coyne Sells 34,791 Shares of Stock
Royalty Pharma PLC (NASDAQ: RPRX - Get Free Report) CFO Terrance Coyne sold 34,791 shares of the company's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $48.33, for a total transaction of $1,681,449.03. Following the transaction, the chief financial officer owned 32,916 shares of the company's stock,
Royalty Pharma and J&J partner to develop autoimmune treatment
Royalty Pharma said on Monday it has signed a $500 million research and development agreement with Johnson & Johnson to advance an experimental antibody treatment for autoimmune diseases.
Royalty Pharma Announces R&D Funding Collaboration for Chronic Immune-Mediated Diseases
NEW YORK, March 30, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced a research and development (R&D) co-funding agreement with Johnson & Johnson for a total of $500 million in 2026 and 2027 to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases.
SG Americas Securities LLC Buys 234,629 Shares of Royalty Pharma PLC $RPRX
SG Americas Securities LLC lifted its stake in Royalty Pharma PLC (NASDAQ: RPRX) by 438.0% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 288,202 shares of the biopharmaceutical company's stock after purchasing an additional 234,629 shares during the
Price Targets
Royalty Pharma price target raised to $57 from $51 at UBS
$57.00
(was $49.30)
Ashwani Verma
·
UBS
Royalty Pharma price target raised to $63 from $61 at Morgan Stanley
$63.00
(was $47.98)
Terence Flynn
·
Morgan Stanley
Royalty Pharma (RPRX) PT Raised to $50 at TD Cowen
$50.00
(was $46.21)
Seaport Global
Royalty Pharma price target raised to $61 from $56 at Morgan Stanley
$61.00
(was $44.71)
Terence Flynn
·
Morgan Stanley
Royalty Pharma upgraded to Buy from Neutral at UBS
$49.00
(was $40.86)
Ashwani Verma
·
UBS
Royalty Pharma (RPRX) PT Raised at TD Cowen; 'Best Ideas 2026: Unique Business'
$45.00
(was $38.22)
Leerink Partners
Royalty Pharma initiated with a Buy at Goldman Sachs
$42.00
(was $35.25)
Goldman Sachs
Royalty Pharma price target raised to $54 from $51 at Morgan Stanley
$54.00
(was $36.14)
Terence Flynn
·
Morgan Stanley
Goldman Sachs Reiterates Buy Rating on Royalty Pharma (RPRX)
$51.00
(was $29.16)
Chris Shibutani
·
Goldman Sachs
Royalty Pharma price target raised to $51 from $48 at Morgan Stanley
$51.00
(was $25.73)
Terence Flynn
·
Morgan Stanley
Royalty Pharma (RPRX) PT Raised to $50 at Goldman Sachs
$50.00
(was $27.09)
Chris Shibutani
·
Goldman Sachs
Royalty Pharma downgraded to Neutral from Buy at UBS
$28.00
(was $27.35)
Ashwani Verma
·
UBS
Morgan Stanley Maintains Overweight on Royalty Pharma, Lowers Price Target to $51
$51.00
(was $42.87)
Morgan Stanley
Royalty Pharma initiated with a Buy at UBS
$47.00
(was $38.46)
Ashwani Verma
·
UBS